Biosimilars Versus ‘Biobetters’—a Regulator’s Perspective

GaBI Journal - Belgium
doi 10.5639/gabij.2014.0304.039
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Pro Pharma Communications International

Related search

An Examination of the Regulatory and Reimbursement Processes for Biobetters and Comparison With Biosimilars

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

A European Perspective on the Market Accessibility of Biosimilars

Biosimilars
2012English

Biosimilars

ESMO Open
Cancer ResearchOncology
2018English

Building a Wall Against Biosimilars

Nature Biotechnology
Applied MicrobiologyBiotechnologyBiomedical EngineeringMolecular MedicineBioengineering
2013English

Biosimilars 2.0

mAbs
AllergyImmunology
2011English

Biosimilars in Medicine

Era's journal of medical research
2017English

Biosimilars: Approval and Acceptance?

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2011English

Mentalism Versus Behaviourism in Economics: A Philosophy-Of-Science Perspective

SSRN Electronic Journal
2012English

Pcp21 - Biosimilars in the Uk – A 2018 Update

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy